BidaskClub downgraded shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) from a hold rating to a sell rating in a research report report published on Thursday morning.

A number of other research analysts also recently commented on LJPC. Jefferies Group LLC reissued a buy rating and issued a $40.00 price objective on shares of La Jolla Pharmaceutical in a research report on Tuesday, July 25th. Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a buy rating to a hold rating in a research report on Tuesday, July 18th. Chardan Capital set a $34.00 price objective on shares of La Jolla Pharmaceutical and gave the company a buy rating in a research report on Monday, May 22nd. SunTrust Banks, Inc. reissued a buy rating and issued a $57.00 price objective on shares of La Jolla Pharmaceutical in a research report on Monday, May 22nd. Finally, Noble Financial reissued a buy rating on shares of La Jolla Pharmaceutical in a research report on Sunday, April 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $43.17.

La Jolla Pharmaceutical (NASDAQ:LJPC) traded up 2.24% on Thursday, reaching $31.48. 121,776 shares of the company’s stock were exchanged. The firm’s market cap is $696.43 million. The firm’s 50-day moving average is $30.87 and its 200-day moving average is $28.33. La Jolla Pharmaceutical has a 12 month low of $14.63 and a 12 month high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by $0.09. La Jolla Pharmaceutical had a negative net margin of 12,692.37% and a negative return on equity of 91.66%. During the same quarter in the prior year, the company posted ($0.90) earnings per share. On average, equities analysts forecast that La Jolla Pharmaceutical will post ($4.96) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “La Jolla Pharmaceutical Company (NASDAQ:LJPC) Downgraded by BidaskClub” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/06/la-jolla-pharmaceutical-company-nasdaqljpc-downgraded-by-bidaskclub.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc boosted its stake in La Jolla Pharmaceutical by 11.6% in the second quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 462 shares in the last quarter. SG Americas Securities LLC bought a new stake in La Jolla Pharmaceutical during the first quarter worth about $195,000. Teza Capital Management LLC bought a new stake in La Jolla Pharmaceutical during the first quarter worth about $204,000. RidgeWorth Capital Management LLC bought a new stake in La Jolla Pharmaceutical during the first quarter worth about $227,000. Finally, American International Group Inc. boosted its stake in La Jolla Pharmaceutical by 7.1% in the first quarter. American International Group Inc. now owns 8,571 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 568 shares in the last quarter.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.